KaloBios Pharmaceuticals, Inc. (OTCMKTS:KBIO) Files An 8-K Regulation FD Disclosure

KaloBios Pharmaceuticals, Inc. (OTCMKTS:KBIO) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01

Regulation FD Disclosure.
KaloBios Pharmaceuticals, Inc. (the Company) intends, from time
to time, to present and/or distribute to the investment community
and utilize at various industry and other conferences the slide
presentation furnished as Exhibit 99.1 hereto.
This Current Report on Form 8-K is being furnished to Item 7.01
of Form 8-K and shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into
any of the Companys filings under the Securities Act of 1933, as
amended, or the Exchange Act, whether made before or after the
date hereof and regardless of any general incorporation language
in such filings, except to the extent expressly set forth by
specific reference in such a filing. The filing of this Item 7.01
of this Current Report on Form 8-K shall not be deemed an
admission as to the materiality of any information herein that is
required to be disclosed solely by reason of Regulation FD.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Investor Presentation dated April 20, 2017

About KaloBios Pharmaceuticals, Inc. (OTCMKTS:KBIO)

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems. It is engaged in developing monoclonal antibodies, lenzilumab, for the treatment of chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia both of which are rare hematologic cancers. It is exploring development of another of its monoclonal antibodies, ifabotuzumab, for the treatment of rare solid and hematologic cancers. Its KB001-A, is a Humaneered, PEGylated, anti-PcrV modified antibody fragment (Fab) antibody developed for the prevention and treatment of Pseudomonas aeruginosa (Pa), infections in mechanically ventilated patients and cystic fibrosis (CF), patients with chronic Pa lung infections.

KaloBios Pharmaceuticals, Inc. (OTCMKTS:KBIO) Recent Trading Information

KaloBios Pharmaceuticals, Inc. (OTCMKTS:KBIO) closed its last trading session up +0.05 at 2.75 with shares trading hands.

An ad to help with our costs